News & Events Year None201820172016201520142013201220112009 08/14/18 REGENXBIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 08/10/18 REGENXBIO Announces Pricing Of Public Offering Of Common Stock 08/08/18 REGENXBIO Announces Proposed Public Offering Of Common Stock 08/08/18 REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia 08/07/18 REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia 08/01/18 REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights 06/12/18 REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I Pagination Current page 1 Page 2 Page 3 Page 4 Next page next › Last page last »
